Telodendrimer-based nanocarriers for the treatment of ovarian cancer

Kai Xiao, Nell Suby, Yuanpei Li, Kit Lam

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

PEG-dendritic block copolymer (telodendrimer) is a unique class of polymers with well-defined structures and tunable aggregation properties, which have been recently developed as novel micelle-based nanocarriers. This new class of nanocarrier is highly versatile, robust, multifunctional and has many unique properties for drug delivery that are superior to most other nanocarriers reported in the literature. Reversible crosslinking of micelles is able to minimize the premature drug release during circulation. These crosslinks can be reversed with endogenous and/or exogenous stimuli. To further facilitate the precise delivery of nanoparticle drugs to cancer cells, the nanoparticles surface can be decorated with ovarian cancer targeting ligands. This review is focused on the various strategies used for the design, preparation, pharmacokinetic, biodistribution and preclinical therapeutic applications of telodendrimer-based nanocarriers for drug delivery in the treatment of ovarian cancer. Lastly, future perspectives for the development of ovarian cancer-targeting telodendrimer nanotherapeutics are also explored.

Original languageEnglish (US)
Pages (from-to)1279-1292
Number of pages14
JournalTherapeutic Delivery
Volume4
Issue number10
DOIs
StatePublished - Oct 2013

Fingerprint

Ovarian Neoplasms
Micelles
Nanoparticles
Pharmaceutical Preparations
Polymers
Pharmacokinetics
Ligands
Neoplasms
Therapeutics
Drug Liberation

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Telodendrimer-based nanocarriers for the treatment of ovarian cancer. / Xiao, Kai; Suby, Nell; Li, Yuanpei; Lam, Kit.

In: Therapeutic Delivery, Vol. 4, No. 10, 10.2013, p. 1279-1292.

Research output: Contribution to journalArticle

@article{265c5a8310c14ddba31ef6077cfac6c6,
title = "Telodendrimer-based nanocarriers for the treatment of ovarian cancer",
abstract = "PEG-dendritic block copolymer (telodendrimer) is a unique class of polymers with well-defined structures and tunable aggregation properties, which have been recently developed as novel micelle-based nanocarriers. This new class of nanocarrier is highly versatile, robust, multifunctional and has many unique properties for drug delivery that are superior to most other nanocarriers reported in the literature. Reversible crosslinking of micelles is able to minimize the premature drug release during circulation. These crosslinks can be reversed with endogenous and/or exogenous stimuli. To further facilitate the precise delivery of nanoparticle drugs to cancer cells, the nanoparticles surface can be decorated with ovarian cancer targeting ligands. This review is focused on the various strategies used for the design, preparation, pharmacokinetic, biodistribution and preclinical therapeutic applications of telodendrimer-based nanocarriers for drug delivery in the treatment of ovarian cancer. Lastly, future perspectives for the development of ovarian cancer-targeting telodendrimer nanotherapeutics are also explored.",
author = "Kai Xiao and Nell Suby and Yuanpei Li and Kit Lam",
year = "2013",
month = "10",
doi = "10.4155/tde.13.91",
language = "English (US)",
volume = "4",
pages = "1279--1292",
journal = "Therapeutic Delivery",
issn = "2041-5990",
publisher = "Future Science",
number = "10",

}

TY - JOUR

T1 - Telodendrimer-based nanocarriers for the treatment of ovarian cancer

AU - Xiao, Kai

AU - Suby, Nell

AU - Li, Yuanpei

AU - Lam, Kit

PY - 2013/10

Y1 - 2013/10

N2 - PEG-dendritic block copolymer (telodendrimer) is a unique class of polymers with well-defined structures and tunable aggregation properties, which have been recently developed as novel micelle-based nanocarriers. This new class of nanocarrier is highly versatile, robust, multifunctional and has many unique properties for drug delivery that are superior to most other nanocarriers reported in the literature. Reversible crosslinking of micelles is able to minimize the premature drug release during circulation. These crosslinks can be reversed with endogenous and/or exogenous stimuli. To further facilitate the precise delivery of nanoparticle drugs to cancer cells, the nanoparticles surface can be decorated with ovarian cancer targeting ligands. This review is focused on the various strategies used for the design, preparation, pharmacokinetic, biodistribution and preclinical therapeutic applications of telodendrimer-based nanocarriers for drug delivery in the treatment of ovarian cancer. Lastly, future perspectives for the development of ovarian cancer-targeting telodendrimer nanotherapeutics are also explored.

AB - PEG-dendritic block copolymer (telodendrimer) is a unique class of polymers with well-defined structures and tunable aggregation properties, which have been recently developed as novel micelle-based nanocarriers. This new class of nanocarrier is highly versatile, robust, multifunctional and has many unique properties for drug delivery that are superior to most other nanocarriers reported in the literature. Reversible crosslinking of micelles is able to minimize the premature drug release during circulation. These crosslinks can be reversed with endogenous and/or exogenous stimuli. To further facilitate the precise delivery of nanoparticle drugs to cancer cells, the nanoparticles surface can be decorated with ovarian cancer targeting ligands. This review is focused on the various strategies used for the design, preparation, pharmacokinetic, biodistribution and preclinical therapeutic applications of telodendrimer-based nanocarriers for drug delivery in the treatment of ovarian cancer. Lastly, future perspectives for the development of ovarian cancer-targeting telodendrimer nanotherapeutics are also explored.

UR - http://www.scopus.com/inward/record.url?scp=84885601638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885601638&partnerID=8YFLogxK

U2 - 10.4155/tde.13.91

DO - 10.4155/tde.13.91

M3 - Article

VL - 4

SP - 1279

EP - 1292

JO - Therapeutic Delivery

JF - Therapeutic Delivery

SN - 2041-5990

IS - 10

ER -